Navigation Links
Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia

xtension rapidly showed significant improvement in memory and cognition, while AC-1202 appeared to have a disease stabilizing effect on subjects expressing the ApoE4 genotype (ApoE4(-)). Regardless of genotype, all subjects who remained on AC- 1202 for all nine months of the study showed very little disease progression, declining only 0.8 points below baseline in ADAS-Cog scores in contrast to the 5.4-point decline observed in placebo subjects extrapolated to nine months.

"The significant and rapid cognitive improvements observed in ApoE4(-) patients support the efficacy observed in our Phase IIa study," said Dr. Lauren Costantini, Accera's vice president of clinical development. "It also provides further evidence of the link between Alzheimer's disease and neuronal hypometabolism," she added, referring to AC-1202's novel mechanism of action.

AC-1202 continued to be well tolerated by subjects in the open-label extension study, providing an additional six months of safety data. The incidence of treatment-related gastrointestinal side effects was similar to that of other AD drugs in the double-blind phase of the study, but a reformulated version of AC-1202 used in the open-label extension study greatly reduced these side effects.

"The excellent safety profile of AC-1202 in addition to its efficacy on top of existing AD drugs makes it a strong candidate for a co-therapeutic approach to the treatment of Alzheimer's disease," said Dr. Steve Orndorff.

Open-label results were highlighted in a "Late Breaking News" press conference today at 1:30 p.m. (EDT) by the Alzheimer's Association. The 2nd Annual International Conference on Prevention of Dementia, a multidisciplinary forum for professionals from the fields of bench research, drug discovery, medicine, care and public policy, is hosted by the Alzheimer's Association, the leading voluntary health organization in Alzheimer care, support and research.

About AC-1202

Brain imaging tec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:3/6/2015)... YORK , March 6, 2015  Pomerantz LLP ... Pharmaceuticals Inc. ("Conatus" or the "Company") (NASDAQ: ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... Conatus and certain of its officers and/or directors have ... Act of 1934.  On March 5, ...
(Date:3/6/2015)... --  Hospira, Inc. (NYSE: HSP ), applauds ... today,s FDA approval of the first biosimilar in ... for improving patient access to safe, effective and more affordable ... has seen first-hand the positive impact of biosimilars in other ... stages of the development of a pathway for these medicines ...
(Date:3/6/2015)... Fla. , March 6, 2015 ... special validation from Intuitive Surgical, the manufacturer of ... their Triton-36 Instrument Cleaning System. This approval reflects ... standards in cleanliness currently in place for the ... special validation for reprocessing robotic surgical instruments for ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Conatus Pharmaceuticals Inc. - CNAT 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 2Hospira Statement on FDA Approval of the First Biosimilar in the United States 3Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2
... /PRNewswire-Asia/ -- Mindray Medical International Limited (NYSE: ... medical devices worldwide, announced today an agreement to acquire ... Ltd. ("Greenlander"). The terms of the agreement were not ... statements. Founded in 2003 and based ...
... Better Health ™, a program of Lilly USA, LLC, (NYSE: ... active lives, has launched an expanded Spanish portal on ... Espanol section features a 60-page interactive health album ... and managing health conditions. Additionally, visitors will find more than ...
Cached Medicine Technology:Mindray Medical to Acquire a Controlling Stake in Zhejiang Greenlander Information Technology 2Mindray Medical to Acquire a Controlling Stake in Zhejiang Greenlander Information Technology 3Lilly for Better Health™ Expands Website to Include Spanish Health Information and Interactive Tools 2Lilly for Better Health™ Expands Website to Include Spanish Health Information and Interactive Tools 3
(Date:3/6/2015)... 06, 2015 First Choice Emergency Room ... new facility is located at 13351 W. Bowles Avenue, Littleton, ... team is ready 24-7 to provide the highest quality emergency ... Medical Director of First Choice Emergency Room Littleton. ... the South Metro Denver Chamber of Commerce and a medical ...
(Date:3/6/2015)... Magellan Rx Management’s 2014 Medical Pharmacy ... key trends and statistics on one of the nation’s ... Magellan Rx Management will discuss key findings from the ... Specialty Drug Spend,” a complimentary March 19 webinar, managed ... drug spend makes up more than a quarter of ...
(Date:3/6/2015)... In a new study conducted at a Warsaw hospital, ... pain was their first mesothelioma symptom. Surviving Mesothelioma has just ... to read it now. , Doctors at the Central ... mesothelioma patients between 2006 and 2012 and found ... that first prompted them to see a doctor. For some, ...
(Date:3/6/2015)... You Wealth Revolution ( http://www.youwealthrevolution.com/info ... ‘energy’ experiment to determine if quick remote meditations ... quick ‘5 -7 minute’ remote energy and consciousness ... their life improving - often times very quickly. ... According to research, respondents saw the following common ...
(Date:3/6/2015)... March 06, 2015 The producers of ... air dates for Spokane, Washington and vicinity. This is a ... shop and dine, and many outdoor activities. It is also ... local economy. Six major hospitals call the city home and ... border. The medically-focused cable TV program will be broadcast on ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:250,000+ Person ‘Remote Energy’ Event has 94.2% of Respondents saying “Life Got Better” 2Health News:The Health Briefs TV Show to Air in Spokane, Washington 2
... ... Public Relations ( http://www.5wpr.com ) , one of the 25 largest PR firms ... Stein ( http://www.philipstein.com/ ) watches to its versatile roster of fashion and ... be a leader in watches and other lifestyle products using proprietary natural frequency ...
... Researchers from the Boston University School of Medicine ... which is over activated in late-stage cancers, is ... patterns of regulatory DNA hypermethylation causing silencing of ... findings, which appear online in Cancer Research ...
... infections, genetics and the environment are complex and mysterious. ... to autoimmune diseases like rheumatoid arthritis and lupus? How ... disease? Our immediate environment interacts with our genetic ... an autoimmune disease, says rheumatologist Prof. Michael Ehrenfeld of ...
... ... with its parent company Logan Consulting, a Chicago IL based consulting and technology firm, effective ... ... Certified partner, today announced it will merge with its parent company Logan Consulting, a Chicago ...
... calories per meal for their children, study found ... information is available on fast-food restaurant menus, parents are ... new research finds. , Often spurred on by legislation, ... about their menu items. But whether this information would ...
... A new, in-home ... disease was presented by lead researcher Dr. Alberto Espay at the American Acadamy of Neurology ... (PRWEB) January ... of gait in people with Parkinson,s disease (PD). , , , , ,It is well ...
Cached Medicine News:Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 2Health News:5W Public Relations Adds Philip Stein Watches to Its Fashion & Lifestyle Client Roster 3Health News:Discovery of epigenetic memory during breast cancer 2Health News:How arthritis thrives 2Health News:Cornerstone Solutions Merges with Logan Consulting 2Health News:Cornerstone Solutions Merges with Logan Consulting 3Health News:Listing Calories on Fast-Food Menus Cuts Kids' Intake 2Health News:Listing Calories on Fast-Food Menus Cuts Kids' Intake 3Health News:New Treatment for Parkinson's Disease Gait Presented at the American Acadamy of Neurology Annual Meeting 2Health News:New Treatment for Parkinson's Disease Gait Presented at the American Acadamy of Neurology Annual Meeting 3
... The CA-1000 counts a Petri dish in ... the optical characteristics of the colonies as ... CA-1000 is equipped with three types of ... lighter or darker than the agar and ...
Basic critical care testing. Measures pH, pCO2, and pO2 from 85 L whole-blood sample....
... sophisticated whole blood analysis system that is ... satisfying the stringent requirements of the central ... all of the components of a traditional ... sampling unit, all of the sensors and ...
The AVL Omni modular system is a complete blood gas solution designed for high-volume critical care use, with customized test combinations, minimum intervention and flexibility....
Medicine Products: